The global peripheral artery disease market size was estimated at USD 7.3 billion in 2024 and is projected to reach USD 11.3 billion by 2033, growing at a CAGR of 5.2% from 2025 to 2033. The intersecting forces of rising disease burden, continuous technological advancement, and demographic aging drive the peripheral artery disease (PAD) industry.
This alignment of unmet clinical needs with evolving therapeutic capabilities accelerates demand across care settings. The growing prevalence of diabetes and tobacco use remains a foundational force driving the market. Both risk factors contribute directly to the progression of atherosclerosis, the core pathological mechanism behind PAD. With diabetes rates climbing globally-particularly in aging, urban populations-and smoking still widespread in lower-income countries, the incidence of PAD continues to rise.
In March 2025, an Intermountain Health study presented at the ACC conference revealed that only 29.6% of women and 33.5% of men with symptomatic peripheral artery disease received full guideline-directed therapy. Among 7,522 patients tracked, the mortality rate exceeded 50%, underscoring severe gaps in diagnosis and treatment. Despite similar referral rates, women were less likely to receive optimal care. The study emphasized the need for improved screening protocols and focused PAD management.
Rapid innovation in endovascular technologies is reshaping treatment strategies and reinforcing market momentum. Next-generation tools such as drug-coated balloons, atherectomy systems, and bioresorbable stents offer improved efficacy, fewer complications, and shorter recovery times. These solutions are increasingly favored for treating complex lesions precisely while reducing restenosis and the need for repeat interventions. In March 2025, a study in Scientific Reports introduced DBMedDet, a deep-learning model that improved stent placement accuracy during endovascular procedures. With high precision (mAP 0.841) and real-time detection (127 FPS), it outperformed YOLO models in identifying stent boundaries across coronary, peripheral, and cerebrovascular cases.
Population aging further amplifies the market potential for PAD interventions, with individuals over 65 facing significantly elevated risk. Age-related arterial stiffening and the accumulation of comorbidities make this demographic especially vulnerable. In March 2025, the Aging Journal published findings from the Long Life Family Study showing individuals from long-lived families have a significantly lower risk of PAD. PAD prevalence among offspring of these families was only 1%, versus an expected 12%. Researchers linked this to protective genetic traits and healthier vascular profiles, identifying four genomic regions potentially tied to PAD resistance.
This product will be delivered within 1-3 business days.
This alignment of unmet clinical needs with evolving therapeutic capabilities accelerates demand across care settings. The growing prevalence of diabetes and tobacco use remains a foundational force driving the market. Both risk factors contribute directly to the progression of atherosclerosis, the core pathological mechanism behind PAD. With diabetes rates climbing globally-particularly in aging, urban populations-and smoking still widespread in lower-income countries, the incidence of PAD continues to rise.
In March 2025, an Intermountain Health study presented at the ACC conference revealed that only 29.6% of women and 33.5% of men with symptomatic peripheral artery disease received full guideline-directed therapy. Among 7,522 patients tracked, the mortality rate exceeded 50%, underscoring severe gaps in diagnosis and treatment. Despite similar referral rates, women were less likely to receive optimal care. The study emphasized the need for improved screening protocols and focused PAD management.
Rapid innovation in endovascular technologies is reshaping treatment strategies and reinforcing market momentum. Next-generation tools such as drug-coated balloons, atherectomy systems, and bioresorbable stents offer improved efficacy, fewer complications, and shorter recovery times. These solutions are increasingly favored for treating complex lesions precisely while reducing restenosis and the need for repeat interventions. In March 2025, a study in Scientific Reports introduced DBMedDet, a deep-learning model that improved stent placement accuracy during endovascular procedures. With high precision (mAP 0.841) and real-time detection (127 FPS), it outperformed YOLO models in identifying stent boundaries across coronary, peripheral, and cerebrovascular cases.
Population aging further amplifies the market potential for PAD interventions, with individuals over 65 facing significantly elevated risk. Age-related arterial stiffening and the accumulation of comorbidities make this demographic especially vulnerable. In March 2025, the Aging Journal published findings from the Long Life Family Study showing individuals from long-lived families have a significantly lower risk of PAD. PAD prevalence among offspring of these families was only 1%, versus an expected 12%. Researchers linked this to protective genetic traits and healthier vascular profiles, identifying four genomic regions potentially tied to PAD resistance.
Global Peripheral Artery Disease Market Report Segmentation
This report forecasts revenue growth at global, regional & country levels and provides an analysis of the industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global peripheral artery disease market report based on device type, anatomical site, end use, and region:Device Type Outlook (Revenue, USD Million, 2021 - 2033)
- Endovascular Devices
- Surgical Devices
Anatomical Site Outlook (Revenue, USD Million, 2021 - 2033)
- Aortoiliac
- Femoropopliteal
- Tibial
End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals
- Outpatient Facilities
- Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Global Peripheral Artery Disease Market Variables, Trends & Scope
Chapter 4. Peripheral Artery Disease Market: Device Type Estimates & Trend Analysis
Chapter 5. Peripheral Artery Disease Market: Anatomical Site Estimates & Trend Analysis
Chapter 6. Peripheral Artery Disease Market: End Use Estimates & Trend Analysis
Chapter 7. Peripheral Artery Disease Market: Regional Estimates & Trend Analysis by Country, Device Type, Anatomical Site & End Use
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- BD
- Bentley InnoMed
- Scitech Medical
- Abbott Laboratories
- Boston Scientific Corporation
- W. L. Gore & Associates, Inc.
- Medtronic
- Cook
- Terumo Corporation
- iVascular
- Getinge AB
- Biotronik SE & Co KG